Target Name: GPR160
NCBI ID: G26996
Review Report on GPR160 Target / Biomarker Content of Review Report on GPR160 Target / Biomarker
GPR160
Other Name(s): GPCR150 | Probable G-protein coupled receptor 160 | putative G protein-coupled receptor | GPCR1 | G protein-coupled receptor 160 | G-protein coupled receptor GPCR1 | hGPCR1 | Putative G protein-coupled receptor | GP160_HUMAN

GPR160: A Potential Drug Target for Diabetes, Obesity and Neurodegenerative Disorders

GPR160 (GPCR150) is a G protein-coupled receptor (GPCR) that is expressed in various tissues of the body, including the brain, pancreas, and gastrointestinal tract. It is involved in the regulation of various physiological processes, including insulin secretion, glucagon secretion, and satiety. GPR160 has also been shown to play a role in pain perception and addiction.

GPR160 is a potential drug target for various diseases, including diabetes, obesity, and neurodegenerative disorders. Its function as a drug target makes it an attractive target for small molecule inhibitors, including those that target its intracellular signaling pathways.

One of the primary intracellular signaling pathways that GPR160 is involved in is the PI3K/Akt signaling pathway. This pathway is involved in the regulation of various cellular processes, including cell survival, cell proliferation, and angiogenesis. GPR160 has been shown to play a role in the regulation of PI3K/Akt signaling pathway, and small molecule inhibitors that target this pathway have been shown to be effective in reducing insulin secretion and body weight in animal models of obesity.

Another intracellular signaling pathway that GPR160 is involved in is the GPCR signaling pathway. This pathway is involved in the regulation of various physiological processes, including sensory perception and neurotransmission. GPR160 has been shown to play a role in the regulation of GPCR signaling pathway, and small molecule inhibitors that target this pathway have been shown to be effective in reducing pain perception and addiction in animal models.

GPR160 is also involved in the regulation of insulin secretion, a critical physiological process that is regulating blood sugar levels. It has been shown that GPR160 plays a role in the regulation of insulin secretion by the pancreatic beta-cells. Small molecule inhibitors that target GPR160 have been shown to be effective in reducing insulin secretion in animal models of insulin resistance.

In addition to its involvement in intracellular signaling pathways, GPR160 is also involved in the regulation of extracellular signaling pathways. It has been shown to play a role in the regulation of cellular adhesion, which is involved in the formation of tight junctions between cells and the formation of tissues. GPR160 has also been shown to play a role in the regulation of tissue inflammation, which is involved in the development of various diseases, including diabetes and neurodegenerative disorders.

GPR160 is a potential drug target for various diseases, including diabetes, obesity, and neurodegenerative disorders. Its function as a drug target makes it an attractive target for small molecule inhibitors that target its intracellular signaling pathways. Further research is needed to fully understand the role of GPR160 as a drug target and to develop effective small molecule inhibitors that target this receptor.

Protein Name: G Protein-coupled Receptor 160

Functions: Orphan receptor

The "GPR160 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GPR160 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

GPR161 | GPR162 | GPR17 | GPR171 | GPR173 | GPR174 | GPR176 | GPR179 | GPR18 | GPR180 | GPR182 | GPR183 | GPR19 | GPR199P | GPR20 | GPR21 | GPR22 | GPR25 | GPR26 | GPR27 | GPR3 | GPR31 | GPR32 | GPR33 | GPR34 | GPR35 | GPR37 | GPR37L1 | GPR39 | GPR4 | GPR42 | GPR45 | GPR50 | GPR52 | GPR55 | GPR6 | GPR61 | GPR62 | GPR63 | GPR65 | GPR68 | GPR75 | GPR75-ASB3 | GPR78 | GPR79 | GPR82 | GPR83 | GPR84 | GPR84-AS1 | GPR85 | GPR87 | GPR88 | GPR89A | GPR89B | GPRACR | GPRASP1 | GPRASP2 | GPRASP3 | GPRC5A | GPRC5B | GPRC5C | GPRC5D | GPRC5D-AS1 | GPRC6A | GPRIN1 | GPRIN2 | GPRIN3 | GPS, PLAT and transmembrane domain-containing protein | GPS1 | GPS2 | GPS2P1 | GPSM1 | GPSM2 | GPSM3 | GPT | GPT2 | GPX1 | GPX1P1 | GPX2 | GPX3 | GPX4 | GPX5 | GPX6 | GPX7 | GPX8 | GRAMD1A | GRAMD1B | GRAMD1C | GRAMD2A | GRAMD2B | GRAMD4 | GRAMD4P2 | GRAMD4P5 | GRAMD4P7 | Granzyme | GRAP | GRAP2 | GRAPL | GRAPL-AS1 | GRASLND